| Popis: |
Gastric adenocarcinoma is one of the most frequent neoplasms in the world. Its incidence varies from country to country, having higher incidences in Japan, Chiles, Finland, and a low incidence in Thailand and in most parts of Africa. In United States, the incidence of gastric cancer has decreased during the last 50 years and actually it has an incidence of 10 cases per 100 000 inhabitants.1 In Albania, in 2008, the population was 3,170,048. According to INSTAT 45% of the population lives in the urban areas, 55% lives in the rural areas. The median survival age is 72.1 years for males and 78.6 years for females (2005-2008). Gastric cancer has a survival rate of 5 years of approximately 5-20%. Yet, there is no standard chemotherapy for patients with gastric cancer in the world. In patients without metastasis and with tumors resectable by surgery, the main therapy (with curative purpose) is surgical excision, followed by chemotherapy or radiotherapy, according to the stage and type of tumor. The carcinomas of the antrum, body and fundus can be divided in two main histologic types: intestinal and diffuse (Lauren classification) which have different causes, different precursor lesions and different growth rates. |
